摘要
人表皮生长因子受体2(HER2)低表达乳腺癌具有较为独特的生物学行为,与HER2零表达乳腺癌相比,在分子分型与基因表达方面存在显著差异。以T-DXd为代表的新型抗体药物偶联物为HER2低表达乳腺癌患者提供了新的治疗选择,相关临床试验在持续开展中。目前,HER2低表达与乳腺癌患者预后的关系尚存争议。对HER2低表达乳腺癌的深入研究将有助于进一步改善该类乳腺癌患者的临床结局。
Breast cancer with low expression of human epidermal growth factor receptor 2(HER2)has unique biological behaviors.Compared with HER2-zero breast cancer,there are significant differences in molecular subtype and gene expression between the two categories of breast cancer.Novel antibody-drug conjugates represented by T-DXd provide a new treatment option for patients with HER2-low breast cancer,and relevant clinical trials are continuing.At present,the relationship between HER2-low status and prognosis of breast cancer patients remains controversial.In-depth research into HER2-low breast cancer will help further improve clinical outcomes for this population.
作者
徐航程
吴云
王佳玉
Xu Hangcheng;Wu Yun;Wang Jiayu(Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)
出处
《国际肿瘤学杂志》
CAS
2022年第9期513-516,共4页
Journal of International Oncology
关键词
乳腺肿瘤
预后
治疗学
人表皮生长因子受体2低表达
Breast neoplasms
Prognosis
Therapeutics
Low expression of human epidermal growth factorreceptor2
